"What you have in this collaboration is two very like-minded, scientifically driven organizations that are coming together to bring very synergistic and complementary technologies to the field of CAR T cells and T-cell-based immunotherapy," said Philip Gregory, chief scientific officer of Bluebird Bio Inc., describing a five-year pact with Regeneron Pharmaceuticals Inc. to discover, develop and commercialize cancer cell therapies.